Geron Corporation

Geron Corporation is a commercial-stage biopharmaceutical company dedicated to changing lives by changing the course of blood cancer. Their primary focus is on telomerase inhibition, a novel therapeutic approach that targets and inhibits the enzyme telomerase, which is upregulated in many malignant cells, driving uncontrolled proliferation. This approach led to the development and commercialization of RYTELO™ (imetelstat), the first and only telomerase inhibitor approved by the FDA, for the treatment of adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.

Geron is exploring the broad potential of telomerase inhibition across multiple myeloid hematologic malignancies, including myelofibrosis (MF) and acute myeloid leukemia (AML). They are currently conducting a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF) and are actively researching imetelstat's potential in other indications, both as a single agent and in combination with standard therapies. Geron's innovative and collaborative culture, fueled by pioneering science and world-class expertise, fuels their commitment to delivering life-changing therapies to patients.

Geron Corporation offers a remote work stipend and a generous paid time off package, which includes vacation, sick, holiday, volunteer day, floating holiday, and paid leave for life events. This indicates a company that values work-life balance and may offer flexible work arrangements, but specific details about remote work policies or schedule flexibility are not explicitly stated.

Geron provides employees with a robust benefits package designed to support healthy, balanced lifestyles. This package includes comprehensive health plans, mental wellness services, company-paid life insurance, employee assistance program, flexible spending accounts, short- and long-term disability insurance, a 401(k) retirement savings plan with employer match, an employee stock purchase plan, voluntary life and disability insurance, wellness and tuition reimbursement programs, a remote work stipend, and generous paid time off for vacation, sick leave, holidays, volunteering, and life events.

Geron Corporation is a commercial-stage biopharmaceutical company dedicated to changing the course of blood cancers and improving the lives of patients. Their mission is focused on developing and commercializing innovative therapies targeting telomerase, an enzyme that plays a key role in the uncontrolled proliferation of malignant cells. Geron is driven by the belief that their pioneering science and commitment to innovation can deliver life-changing treatments for those battling blood cancers.

Geron promotes a collaborative and innovative culture where each employee's contributions are valued. They see their team as the foundation for their success, emphasizing the unique strengths of each individual and the impact of every employee. This collaborative environment encourages open communication and recognizes the importance of working together to achieve their mission of changing lives by changing the course of blood cancer.

Geron Corporation values diversity, equity, and inclusion, recognizing that the unique strengths and contributions of each team member are essential to advancing their mission. They are committed to fostering a culture that attracts and retains talent from diverse backgrounds and ensuring that all employees feel valued, respected, and have equal opportunities for growth and success.